Literature DB >> 21748485

Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias.

J A Johnson1, S L Bowker, K Richardson, C A Marra.   

Abstract

AIMS/HYPOTHESIS: Despite the vast body of epidemiological literature on the risk of cancer in people with diabetes, few studies have examined the pattern of cancer risk during different time windows following diabetes onset. The objective of the study was to examine the risks of site-specific cancer in people with incident type 2 diabetes during different time windows following diabetes onset.
METHODS: This was a population-based retrospective cohort study. The study period was 1 April 1994 to 31 March 2006; censoring occurred at 31 March 2006, at death or on departure from British Columbia, Canada. Using linked health databases, we identified incident cohorts with and without diabetes, who were matched by age, sex and index year. Following a minimum 2-year cancer washout period, first site-specific cancers were identified prospectively in both cohorts.
RESULTS: Within 3 months following diabetes onset, participants with diabetes had significantly increased risks of colorectal, lung, liver, cervical, endometrial, ovarian, pancreatic and prostate cancers. After the initial 3-month period, the risks for colorectal (HR 1.15, 95% CI 1.05, 1.25), liver (HR 2.53, 95% CI 1.93, 3.31) and endometrial (HR 1.58, 95% CI 1.28, 1.94) cancers remained significantly elevated compared with those without diabetes. The diabetes cohort remained at increased risk of pancreatic cancer in later years, but followed a different pattern: HR 3.71 at 3 months-1 year, 2.94 at 1-2 years, 1.78 at 2-3 years and 1.65 at 3-10 years (p value for all <0.01). After an initial period of elevated risk, men with type 2 diabetes subsequently had a decreased risk of prostate cancer (HR 0.82, 95% CI 0.76, 0.88). CONCLUSIONS/
INTERPRETATION: People with type 2 diabetes are at increased risk of select cancers; this risk is particularly elevated at the time of diabetes onset, which is likely to be due to increased ascertainment.

Entities:  

Mesh:

Year:  2011        PMID: 21748485     DOI: 10.1007/s00125-011-2242-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  13 in total

1.  The development of the National Diabetes Surveillance System (NDSS) in Canada.

Authors:  C Clottey; F Mo; B LeBrun; P Mickelson; J Niles; G Robbins
Journal:  Chronic Dis Can       Date:  2001

Review 2.  Epidemiological aspects of neoplasms in diabetes.

Authors:  Antonio Nicolucci
Journal:  Acta Diabetol       Date:  2010-04-08       Impact factor: 4.280

3.  Creating a population-based linked health database: a new resource for health services research.

Authors:  R Chamberlayne; B Green; M L Barer; C Hertzman; W J Lawrence; S B Sheps
Journal:  Can J Public Health       Date:  1998 Jul-Aug

4.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm.

Authors:  Janet E Hux; Frank Ivis; Virginia Flintoft; Adina Bica
Journal:  Diabetes Care       Date:  2002-03       Impact factor: 19.112

5.  Diabetes mellitus and risk of breast cancer: a meta-analysis.

Authors:  Susanna C Larsson; Christos S Mantzoros; Alicja Wolk
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

6.  Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.

Authors:  Louise Pilote; Christine A Beck; Igor Karp; David Alter; Peter Austin; Jafna Cox; Karin Humphries; Cynthia Jackevicius; Hugues Richard; Jack V Tu
Journal:  Can J Cardiol       Date:  2004-01       Impact factor: 5.223

7.  Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Authors:  Sebastian Schneeweiss; Colin Dormuth; Paul Grootendorst; Stephen B Soumerai; Malcolm Maclure
Journal:  Med Care       Date:  2004-07       Impact factor: 2.983

8.  Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

Authors:  Sebastian Schneeweiss; Malcolm Maclure; Bruce Carleton; Robert J Glynn; Jerry Avorn
Journal:  BMJ       Date:  2004-02-24

9.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.

Authors:  R Huxley; A Ansary-Moghaddam; A Berrington de González; F Barzi; M Woodward
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

10.  Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data.

Authors:  Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Malcolm Maclure; Raia Levin; Robert J Glynn
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 6.473

View more
  64 in total

Review 1.  The epidemiology of diabetes and cancer.

Authors:  Bendix Carstensen; Marit Eika Jørgensen; Søren Friis
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

2.  Body mass index and mortality in patients with gastric cancer: a large cohort study.

Authors:  Jung Hwan Lee; Boram Park; Jungnam Joo; Myeong-Cherl Kook; Young-Il Kim; Jong Yeul Lee; Chan Gyoo Kim; Il Ju Choi; Bang Wool Eom; Hong Man Yoon; Keun Won Ryu; Young-Woo Kim; Soo-Jeong Cho
Journal:  Gastric Cancer       Date:  2018-04-12       Impact factor: 7.370

3.  Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.

Authors:  Phyo T Htoo; John B Buse; Mugdha Gokhale; M Alison Marquis; Virginia Pate; Til Stürmer
Journal:  Eur J Clin Pharmacol       Date:  2016-05-10       Impact factor: 2.953

Review 4.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.

Authors:  J A Johnson; B Carstensen; D Witte; S L Bowker; L Lipscombe; A G Renehan
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

Review 5.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

6.  Insulin analogues and cancer risk: the emergence of second-generation studies.

Authors:  A G Renehan
Journal:  Diabetologia       Date:  2011-10-28       Impact factor: 10.122

7.  Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.

Authors:  Phyo T Htoo; Til Stürmer; Michele Jonsson-Funk; Virginia Pate; Ross J Simpson; Jennifer L Lund
Journal:  Epidemiology       Date:  2019-11       Impact factor: 4.822

8.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

9.  Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size.

Authors:  Jay H Fowke; Saundra Motley; Qi Dai; Raoul Concepcion; Daniel A Barocas
Journal:  Cancer Lett       Date:  2012-10-16       Impact factor: 8.679

Review 10.  Diabetes mellitus and metformin in hepatocellular carcinoma.

Authors:  Koji Fujita; Hisakazu Iwama; Hisaaki Miyoshi; Joji Tani; Kyoko Oura; Tomoko Tadokoro; Teppei Sakamoto; Takako Nomura; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.